Post by David Grey on Jan 10, 2018 13:43:00 GMT -5
The study is an out-patient, randomized, -label, multiple dose, parallel study to assess the immunogenicity of multiple subcutaneous (SC) doses of PF-06881894 and the pegfilgrastim-US reference product in healthy volunteers. Appmately 420 healthy volunteers (appmately equal numbers of male and female subjects) will be enrolled and randomized to 1 of 2 treatments: PF-06881894(Regimen A) or pegfilgrastim-US reference product (Regimen B)
3898 N.W. 7Th Street
Miami, FL 33126
(305) 644-9903
Sponsored By: Quotient Sciences
Stipend: $2540 - $2540
Length of Study: 12 weeks
Research Facility: Out-Patient
Gender: Both
Age: 18 - 65
Washout Period: 30 days from Last Dosing Date to Admission
Health Condition: *Healthy Volunteers Studies
More Information: No alcohol within 48 hours of day 1 of any study period and ue abstaining
through Day 5 of each study period
No tobacco use for at least 90 days prior to dosing
Body weight between 50-100 kg (110-220 pounds)
3898 N.W. 7Th Street
Miami, FL 33126
(305) 644-9903
Sponsored By: Quotient Sciences
Stipend: $2540 - $2540
Length of Study: 12 weeks
Research Facility: Out-Patient
Gender: Both
Age: 18 - 65
Washout Period: 30 days from Last Dosing Date to Admission
Health Condition: *Healthy Volunteers Studies
More Information: No alcohol within 48 hours of day 1 of any study period and ue abstaining
through Day 5 of each study period
No tobacco use for at least 90 days prior to dosing
Body weight between 50-100 kg (110-220 pounds)